Toll-like receptor 9

Immunitas Therapeutics Appoints Annalisa D'Andrea, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, January 18, 2024

WALTHAM, Mass., Jan. 18, 2024 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced the appointment of Annalisa D'Andrea, Ph.D., as Chief Scientific Officer (CSO). Dr. D'Andrea has more than 25 years of basic and translational research and development expertise in both large and small pharmaceutical and biotech settings.

Key Points: 
  • Dr. D'Andrea brings more than 25 years of research and development experience to the company, expanding executive leadership team to advance pipeline
    WALTHAM, Mass., Jan. 18, 2024 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced the appointment of Annalisa D'Andrea, Ph.D., as Chief Scientific Officer (CSO).
  • Dr. D'Andrea brings to Immunitas a strong history of success in immunology therapeutic development, having led products from target selection through clinical evaluation.
  • "Annalisa's leadership and deep drug development expertise has proven invaluable as we advanced our growing pipeline of novel precision immuno-oncology therapeutics over the past several months," said Amanda Wagner, Chief Executive Officer of Immunitas.
  • "We are excited to welcome her as our full-time Chief Scientific Officer.

EQS-News: Secarna Pharmaceuticals announces publication of new preclinical data showing durable antitumor activity of LNAplus™-based ASOs that both stimulate the innate immune system and suppress PD-L1 expressi

Retrieved on: 
Monday, June 5, 2023

TLR9 signaling is an important innate immune pathway that is relevant as a first-line defense mechanism against pathogens.

Key Points: 
  • TLR9 signaling is an important innate immune pathway that is relevant as a first-line defense mechanism against pathogens.
  • A drawback to this approach is that the TLR9 –mediated immune response is blunted by immediate upregulation of immune checkpoints such as PD-L1.
  • The combined downregulation of PD-L1 expression in a single-molecule approach resulted in exceptional antitumor activity in different tumor models.
  • “Our recently published data demonstrate the potential therapeutic effect of simultaneously targeting TLR9 and PD-L1, key modulators of the innate and adaptive immune system, respectively, with a bimodal ASO.

InDex Pharmaceuticals to attend the ECCO 2023 congress

Retrieved on: 
Monday, February 27, 2023

STOCKHOLM, Feb. 27, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the company will attend the annual congress of the European Crohn's and Colitis Organisation (ECCO), March 1-4, 2023 in Copenhagen.

Key Points: 
  • STOCKHOLM, Feb. 27, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the company will attend the annual congress of the European Crohn's and Colitis Organisation (ECCO), March 1-4, 2023 in Copenhagen.
  • ECCO is the largest forum for specialists in inflammatory bowel disease globally.
  • InDex Pharmaceuticals will also be present at booth #C3-17 in the exhibition hall at the Bella Center.
  • "ECCO is the largest forum for specialists in inflammatory bowel disease in the world and a very significant industry and healthcare professional event," said Jenny Sundqvist, CEO of InDex Pharmaceuticals.

InDex Pharmaceuticals to attend the ECCO 2023 congress

Retrieved on: 
Monday, February 27, 2023

STOCKHOLM, Feb. 27, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the company will attend the annual congress of the European Crohn's and Colitis Organisation (ECCO), March 1-4, 2023 in Copenhagen.

Key Points: 
  • STOCKHOLM, Feb. 27, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) today announced that the company will attend the annual congress of the European Crohn's and Colitis Organisation (ECCO), March 1-4, 2023 in Copenhagen.
  • ECCO is the largest forum for specialists in inflammatory bowel disease globally.
  • InDex Pharmaceuticals will also be present at booth #C3-17 in the exhibition hall at the Bella Center.
  • "ECCO is the largest forum for specialists in inflammatory bowel disease in the world and a very significant industry and healthcare professional event," said Jenny Sundqvist, CEO of InDex Pharmaceuticals.